Skip to main content

53 Result(s)

within H-J Lenz Remove this filter English Remove this filter

previous disabled Page of 3
and

  1. Article

    Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth

    A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01759-9

    J. Stebbing, H. Zhang, Y. Xu, L. C. Lit, A. R. Green, A. Grothey, Y. Lombardo… in Oncogene (2021)

    Download PDF (164 KB) View Article

  2. No Access

    Article

    Prognostic impact of FOXF1 polymorphisms in gastric cancer patients

    A recent genome-wide association study identified seven single-nucleotide polymorphisms (SNPs) in region 16q24, near the Forkhead box-F1 (FOXF1) gene, which confer susceptibility to esophageal adenocarcinoma. We ...

    S Matsusaka, A H Wu, S Cao, D L Hanna, K Chin, D Yang… in The Pharmacogenomics Journal (2018)

  3. No Access

    Article

    DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies

    Colorectal cancer (CRC) is a worldwide health concern with respect to both incidence and mortality, and as a result, CRC tumorigenesis, progression and metastasis have been heavily studied, especially with res...

    D J Weisenberger, G Liang, H-J Lenz in Oncogene (2018)

  4. No Access

    Article

    A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

    The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymo...

    A Sebio, S Stintzing, V Heinemann, Y Sunakawa, W Zhang… in The Pharmacogenomics Journal (2018)

  5. No Access

    Article

    Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients

    Using approved methods, circulating tumor cells (CTCs) are only isolated from blood in 30%–50% of metastatic colorectal cancer (mCRC) patients. We previously validated a technique to isolate circulating tumor ...

    Y Ning, W Zhang, D L Hanna, D Yang, S Okazaki, M D Berger… in The Pharmacogenomics Journal (2018)

  6. No Access

    Article

    Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer

    Immunomodulator-targeting therapies are under development in gastric cancer (GC). However, the role of genes modulating anti-tumor immunity in GC remains poorly understood. We investigated the association of v...

    Y Sunakawa, S Cao, N B Volz, M D Berger, D Yang, A Parekh… in The Pharmacogenomics Journal (2017)

  7. No Access

    Article

    Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis

    Studies of germline polymorphisms as predictors of tumor response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody agents in metastatic colorectal cancer have reported inconsistent results. ...

    E K Morgen, H-J Lenz, D J Jonker, D Tu, G Milano… in The Pharmacogenomics Journal (2017)

  8. No Access

    Article

    CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

    We analyzed associations between CXCR4/CXCL12 single-nucleotide polymorphisms and outcomes in metastatic colorectal cancer (mCRC) patients who underwent first-line bevacizumab-based chemotherapy. A total of 874 p...

    S Matsusaka, S Cao, D L Hanna, Y Sunakawa, M Ueno… in The Pharmacogenomics Journal (2017)

  9. No Access

    Article

    Genetic variants associated with colorectal brain metastases susceptibility and survival

    Colorectal brain metastases (BM) are rare (1–2%) and a late-stage disease manifestation. Molecular mechanisms for BM development are not well understood. We tested whether variants within genes involved in ove...

    S Stremitzer, A S Berghoff, N B Volz, W Zhang, D Yang… in The Pharmacogenomics Journal (2017)

  10. No Access

    Article

    Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer

    Estrogen has been shown not only to reduce the incidence of colorectal cancer but also gastric cancer (GC). Polymorphisms in estrogen receptor β gene, ESR2, correlate with colorectal cancer survival. To better un...

    Y Sunakawa, S Cao, M D Berger, S Matsusaka, D Yang, W Zhang… in The Pharmacogenomics Journal (2017)

  11. No Access

    Article

    Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer

    The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil (5-Fu). In this study, 14 polymorphisms in 8 g...

    A Sebio, S Matsusaka, W Zhang, D Yang, Y Ning, S Stremitzer… in The Pharmacogenomics Journal (2016)

  12. No Access

    Article

    Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases

    In patients with colorectal liver metastases (CLM), liver resection offers the possibility of cure and long-term survival. The liver is a highly immunogenic organ harboring ~80% of the body’s tissue macrophage...

    S Stremitzer, Y Sunakawa, W Zhang, D Yang, Y Ning… in The Pharmacogenomics Journal (2015)

  13. Article

    Open Access

    LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy

    We recently found variants in cancer stem cell genes (CD44, ALCAM and LGR5) significantly associated with increased time to recurrence (TTR) in patients with stage III and high-risk stage II colon cancer treated ...

    J Szkandera, S Herzog, M Pichler, V Stiegelbauer, M Stotz… in The Pharmacogenomics Journal (2015)

    Download PDF (299 KB) View Article

  14. No Access

    Article

    Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy

    Colorectal cancer (CRC) is a heterogeneous disease with genetic profiles and clinical outcomes dependent on the anatomic location of the primary tumor. How location has an impact on the molecular makeup of a t...

    M K H Maus, D L Hanna, C L Stephens, S H Astrow, D Yang… in The Pharmacogenomics Journal (2015)

  15. No Access

    Article

    Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer

    In patients with breast cancer (BC), deregulation of estrogen receptor (ERα) activity may account for most resistance to endocrine therapies. Our previous study used a whole-human kinome siRNA screen to identi...

    L Benhaim, W Zhang, T Wakatsuki, D Yang, A Gerger… in The Pharmacogenomics Journal (2015)

  16. No Access

    Article

    Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer

    Integrins (ITGs) are key elements in cancer biology, regulating tumor growth, angiogenesis and lymphangiogenesis through interactions of the tumor cells with the microenvironment. Moving from the hypothesis th...

    P Bohanes, D Yang, F Loupakis, M J LaBonte, A Gerger… in The Pharmacogenomics Journal (2015)

  17. No Access

    Article

    KSR1 regulates BRCA1 degradation and inhibits breast cancer growth

    Kinase suppressor of Ras-1 (KSR1) facilitates signal transduction in Ras-dependent cancers, including pancreatic and lung carcinomas but its role in breast cancer has not been well studied. Here, we demonstrat...

    J Stebbing, H Zhang, Y Xu, L C Lit, A R Green, A Grothey, Y Lombardo… in Oncogene (2015)

  18. Article

    Open Access

    Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

    Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated with sunitin...

    A J Zurita, M Khajavi, H-K Wu, L Tye, X Huang, M H Kulke… in British Journal of Cancer (2015)

    Download PDF (371 KB) View Article

  19. No Access

    Article

    Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

    Pericytes are crucial for angiogenesis. The impact of pericyte function to bevacizumab efficacy in mCRC treatment has not been comprehensively examined. This retrospective study investigated germline polymorph...

    N B Volz, S Stintzing, W Zhang, D Yang, Y Ning, T Wakatsuki… in The Pharmacogenomics Journal (2015)

  20. Article

    Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

    H. S. Hochster, N. Uboha, W. Messersmith… in Cancer Chemotherapy and Pharmacology (2015)

    Download PDF (102 KB) View Article
previous disabled Page of 3